치료 기기 시장 : 시장 규모, 점유율, 동향 분석(용도별, 최종 용도별, 지역별), 부문별 예측(2026-2033년)

Therapy Devices Market Summary

The global therapy devices market size was estimated at USD 27.23 billion in 2025 and is projected to reach USD 47.06 billion by 2033, growing at a CAGR of 6.09% from 2026 to 2033. The growth is attributed to the growing burden of pain & musculoskeletal disorders and rising adoption of advanced neurotherapy and mental health solutions.

For instance, according to the report The State of Musculoskeletal Health 2024 published by the Versus Arthritis Organization, more than 10 million people in the UK have arthritis. In addition, around 27,000 adults are newly diagnosed with rheumatoid arthritis each year in the UK. The rise in chronic respiratory diseases and growing geriatric population further contribute to market growth. Moreover, growing shift towards home-based and self-administered therapy and supportive initiatives by government and private organizations drive market growth further.

The increasing prevalence of chronic pain and musculoskeletal disorders is a significant driver for the market. This increasing prevalence is accelerating the demand for device-based, non-pharmacological therapies. Conditions such as arthritis, lower back pain, sports injuries, post-operative pain, and age-related mobility impairment require repetitive, localized, and long-term therapeutic intervention, optimally delivered through therapy devices rather than episodic drug treatment. This drives the adoption of electrical stimulation (TENS, NMES), ultrasound therapy, cryotherapy, thermotherapy, and laser therapy devices across clinical and home care settings. According to Hinge Health's annual State of Musculoskeletal (MSK) Care Report, approximately 40% of adults in the U.S. are affected by MSK conditions.

Moreover, technological innovation in rehabilitation and physical therapy is a key factor driving market growth. Advanced therapy devices now integrate robotics, motorized assistance, and sensor-based systems to support recovery from stroke, orthopedic injuries, neurological disorders, and age-related mobility decline. Robotic-assisted gait trainers, exoskeletons, and automated therapy platforms enable repetitive, high-intensity, and task-specific rehabilitation that is difficult to achieve through manual therapy alone. These technologies improve functional outcomes, reduce therapist fatigue, and increase therapy consistency, driving adoption across hospitals, rehabilitation centers, and specialty clinics. For instance, in January 2025, IIT Kanpur introduced a Brain-Computer Interface (BCI)-based robotic hand exoskeleton for stroke recovery, integrating brain signals with therapeutic movements via closed-loop control.

In addition, Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition that affects approximately 11% of adults aged over 25 years, with global COPD cases projected to grow by 23.3% to reach nearly 592 million by 2050. The rising prevalence of chronic respiratory diseases represents a high-impact driver for market growth. In addition, increasing awareness of respiratory comorbidities particularly obstructive sleep apnea (OSA) among COPD patients is contributing to higher diagnosis rates and expanding treatment demand, thereby supporting sustained market expansion.

Government and private-sector initiatives are accelerating the adoption of therapy devices by expanding access, funding, and institutional readiness for device-based therapeutic care. Public health programs targeting chronic disease management, disability rehabilitation, respiratory care, and mental health increasingly incorporate therapy devices as standard care tools. Government-backed investments in rehabilitation centers, pulmonary care units, and community health infrastructure create sustained demand for respiratory therapy devices, rehabilitation systems, neurotherapy devices, and pain management equipment. For instance, in the U.S., the CDC has included sleep apnea in its broader public health messaging about sleep hygiene and chronic disease management. Similarly, in the UK, the National Health Service (NHS) promotes sleep health awareness and encourages people to seek diagnostic testing for sleep apnea.

Global Therapy Devices Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global therapy devices market report based on application, end use, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Pain Management
  • Electrical Stimulation (TENS/NMES)
  • Cryo / Thermotherapy
  • Laser therapy
  • Ultrasound Therapy
• Rehabilitation & Physical Therapy
  • Robotic Rehabilitation Systems
  • Virtual Reality Therapy Systems
  • Exoskeleton Devices
  • Electromechanical Therapy Platforms
• Mental Health & Neurotherapy
  • Neurostimulation (tDCS, TMS)
  • EEG-based Neurofeedback Devices
• Respiratory Therapy
  • CPAP / BiPAP
  • Non-Invasive Ventilators/Resuscitators
  • Pulmonary Rehab Devices
  • Nebulizers / Aerosol Systems
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Specialty Clinics
• Rehabilitation Centers
• Home-care & Consumer Use
• Long-term Care Facilities
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Methodology
• 1.8. Information Procurement
• 1.9. Market-Specific Research Models
  • 1.9.1. Consensus-based Estimates & Forecasting
• 1.10. Primary Research Methodology
• 1.11. List of Secondary Sources
• 1.12. List of Primary Sources

Chapter 2. Therapy Devices Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. End Use Outlook
• 2.3. Competitive Insights

Chapter 3. Therapy Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Burden of Pain & Musculoskeletal Disorders and Rising Adoption of Advanced Neurotherapy and Mental Health Solutions
    • 3.2.1.2. Rise In Chronic Respiratory Diseases and Growing Geriatric Population
    • 3.2.1.3. Growing Shift Towards Home-Based and Self-Administered Therapy
    • 3.2.1.4. Supportive Initiatives by Government and Private Organizations
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Product Recalls and Device Failure
    • 3.2.2.2. Complex Regulatory Framework for Therapy Devices
  • 3.2.3. Industry Opportunity Analysis
    • 3.2.3.1. Growing Number of Rehabilitation Centers in Developing Countries
    • 3.2.3.2. Shift Toward Minimally Invasive & Non-Invasive Therapies
    • 3.2.3.3. Integration Of AI, Digital Health, And Smart Therapy Devices
    • 3.2.3.4. Growing Adoption of Personalized and Precision Therapy
• 3.3. Regional EMS Ecosystem Overview
• 3.4. OEM vs EMS Manufacturing Model Assessment
• 3.5. Outsourcing Penetration by Therapy Device Sub-Segment
• 3.6. Evolution of Therapy Device Design & Technology
• 3.7. Value Chain Analysis (PCBA, System Integration, Testing, Final Assembly)
• 3.8. Global Therapy Devices: Market Analysis Tools
  • 3.8.1. Industry Analysis - Porter's Five Forces Analysis
  • 3.8.2. PESTLE Analysis

Chapter 4. Therapy Devices Market Segment Analysis, By Application (Revenue in USD Million, 2021 - 2033)

• 4.1. Application Market Share Analysis, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Therapy Devices Market By Application Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For the Following
  • 4.4.1. Pain Management
    • 4.4.1.1. Pain Management Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.1.2. Electrical Stimulation (TENS/NMES)
      • 4.4.1.2.1. Electrical Stimulation (TENS/NMES) Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.1.3. Cryo / Thermotherapy
      • 4.4.1.3.1. Cryo / Thermotherapy Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.1.4. Laser Therapy
      • 4.4.1.4.1. Laser Therapy Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.1.5. Ultrasound Therapy
      • 4.4.1.5.1. Ultrasound Therapy Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.2. Rehabilitation & Physical Therapy
    • 4.4.2.1. Rehabilitation & Physical Therapy Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.2.2. Robotic Rehabilitation Systems
      • 4.4.2.2.1. Robotic Rehabilitation Systems Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.2.3. Virtual Reality Therapy Systems
      • 4.4.2.3.1. Virtual Reality Therapy Systems Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.2.4. Exoskeleton Devices
      • 4.4.2.4.1. Exoskeleton Devices Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.2.5. Electromechanical Therapy Platforms
      • 4.4.2.5.1. Electromechanical Therapy Platforms Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.3. Mental Health & Neurotherapy
    • 4.4.3.1. Mental Health & Neurotherapy Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.3.2. Neurostimulation (tDCS, TMS)
      • 4.4.3.2.1. Neurostimulation (tDCS, TMS) Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.3.3. EEG-based Neurofeedback Devices
      • 4.4.3.3.1. EEG-based Neurofeedback Devices Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.4. Respiratory Therapy
    • 4.4.4.1. Respiratory Therapy Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.4.2. CPAP / BiPAP
      • 4.4.4.2.1. CPAP / BiPAP Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.4.3. Non-invasive ventilators/Resuscitators
      • 4.4.4.3.1. Non-invasive ventilators/Resuscitators Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.4.4. Pulmonary Rehab Devices
      • 4.4.4.4.1. Pulmonary Rehab Devices Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 4.4.4.5. Nebulizers / Aerosol Systems
      • 4.4.4.5.1. Nebulizers / Aerosol Systems Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 5. Therapy Devices Market Segment Analysis, By End Use (Revenue in USD Million, 2021 - 2033)

• 5.1. Definition and Scope
• 5.2. End Use Market Share Analysis, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Therapy Devices Market By End Use Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For the Following
  • 5.5.1. Hospitals & Specialty Clinics
    • 5.5.1.1. Hospitals & Specialty Clinics Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.5.2. Rehabilitation Centers
    • 5.5.2.1. Rehabilitation Centers Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.5.3. Home-care & Consumer Use
    • 5.5.3.1. Home-care & Consumer Use Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 5.5.4. Long-term Care Facilities
    • 5.5.4.1. Long-term Care Facilities Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 6. Therapy Devices Market Segment Analysis, By Region, (Revenue in USD Million, 2021 - 2033)

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Therapy Devices Market Share by Region, 2025 & 2033:
• 6.5. North America
  • 6.5.1. North America Therapy Devices Market, 2021 - 2033 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. U.S. Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Canada Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Mexico Therapy Devices Market, 2021 To 2033 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. UK Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Germany Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.4. Spain
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Spain Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.5. France
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. France Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.6. Italy
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Italy Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.7. Denmark
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Denmark Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Competitive Scenario
    • 6.6.8.3. Regulatory Framework
    • 6.6.8.4. Sweden Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.6.9. Norway
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Competitive Scenario
    • 6.6.9.3. Regulatory Framework
    • 6.6.9.4. Norway Therapy Devices Market, 2021 To 2033 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Competitive Scenario
    • 6.7.1.3. Regulatory Framework
    • 6.7.1.4. Japan Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. China Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. India Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.7.4. South Korea
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. South Korea Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.7.5. Thailand
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Thailand Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.7.6. Australia
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Australia Therapy Devices Market, 2021 To 2033 (USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America Therapy Devices Market, 2021 - 2033 (USD Million)
  • 6.8.2. Brazil
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Brazil Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Argentina Therapy Devices Market, 2021 To 2033 (USD Million)
• 6.9. MEA
  • 6.9.1. MEA Therapy Devices Market, 2021 - 2033 (USD Million)
  • 6.9.2. South Africa
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. South Africa Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Saudi Arabia Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key Country Dynamics
    • 6.9.4.2. Competitive Scenario
    • 6.9.4.3. Regulatory Framework
    • 6.9.4.4. UAE Therapy Devices Market, 2021 To 2033 (USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key Country Dynamics
    • 6.9.5.2. Competitive Scenario
    • 6.9.5.3. Regulatory Framework
    • 6.9.5.4. Kuwait Therapy Devices Market, 2021 To 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Pain Management Devices
  • 7.1.1. Participant's Overview
    • 7.1.1.1. Top 30 Pain Management Devices Participant
    • 7.1.1.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.1.1.3. EMS Providers in Pearl River Delta
  • 7.1.2. R&D Focus and Sales Channel Analysis
    • 7.1.2.1. Top 30 Pain Management Devices Participant
    • 7.1.2.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.1.2.3. EMS Providers in Pearl River Delta
  • 7.1.3. Financial Performance
    • 7.1.3.1. Top 30 Pain Management Devices Participant
    • 7.1.3.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.1.3.3. EMS Providers in Pearl River Delta
  • 7.1.4. Product Benchmarking
    • 7.1.4.1. Top 30 Pain Management Devices Participant
    • 7.1.4.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.1.4.3. EMS Providers in Pearl River Delta
  • 7.1.5. SWOT Analysis
    • 7.1.5.1. Top 30 Pain Management Devices Participant
    • 7.1.5.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.1.5.3. EMS Providers in Pearl River Delta
  • 7.1.6. Strategy Mapping
    • 7.1.6.1. Product launch
    • 7.1.6.2. Mergers & acquisition
    • 7.1.6.3. Partnerships & collaboration
    • 7.1.6.4. Expansion
    • 7.1.6.5. Other strategies
• 7.2. Company Market Share Analysis, 2025
  • 7.2.1. Pain Management Devices
    • 7.2.1.1. Top 30 Pain Management Devices Participant
    • 7.2.1.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.2.1.3. EMS Providers in Pearl River Delta
  • 7.2.2. Rehabilitation & Physical Therapy Devices
    • 7.2.2.1. Top 30 Rehabilitation & Physical Therapy Devices Participant
    • 7.2.2.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.2.2.3. EMS Providers in Pearl River Delta
  • 7.2.3. Respiratory Therapy Devices
    • 7.2.3.1. Top 30 Respiratory Therapy Devices Participant
    • 7.2.3.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.2.3.3. EMS Providers in Pearl River Delta
  • 7.2.4. Mental Health & Neurotherapy Devices
    • 7.2.4.1. Top 30 Mental Health & Neurotherapy Devices Participant
    • 7.2.4.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.2.4.3. EMS Providers in Pearl River Delta
  • 7.2.5. Other Therapy Devices
    • 7.2.5.1. Top 30 Other Therapy Devices Participant
    • 7.2.5.2. Brand-Owned, R&D-Driven Companies That Do Not Have In-House Manufacturing and Require EMS Partners
    • 7.2.5.3. EMS Providers in Pearl River Delta
• 7.3. Company Profiles, Pain Management
  • 7.3.1. PAJUNK
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Product Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. OMRON Healthcare, Inc.
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Product Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Zynex Medical
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Product Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Litemed
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Product Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. DJO Global
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Product Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. Boston Scientific Corporation
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Product Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. SPR
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Product Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Medtronic
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Product Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Nalu Medical, Inc.
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Product Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Abbott
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Product Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Atricure, Inc.
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Product Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. ThermaCare
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Product Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Avanos Medical, Inc
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Product Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. ICU Medical, Inc.
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Product Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Dynatronics Corporation
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Product Benchmarking
    • 7.3.15.4. Strategic Initiatives
  • 7.3.16. RS Medical
    • 7.3.16.1. Company Overview
    • 7.3.16.2. Financial Performance
    • 7.3.16.3. Product Benchmarking
    • 7.3.16.4. Strategic Initiatives
  • 7.3.17. Bioventus
    • 7.3.17.1. Company Overview
    • 7.3.17.2. Financial Performance
    • 7.3.17.3. Product Benchmarking
    • 7.3.17.4. Strategic Initiatives
  • 7.3.18. BioElectronics Corporation
    • 7.3.18.1. Company Overview
    • 7.3.18.2. Financial Performance
    • 7.3.18.3. Product Benchmarking
    • 7.3.18.4. Strategic Initiatives
  • 7.3.19. ProMedTek Inc.
    • 7.3.19.1. Company Overview
    • 7.3.19.2. Financial Performance
    • 7.3.19.3. Product Benchmarking
    • 7.3.19.4. Strategic Initiatives
  • 7.3.20. InfuSystem
    • 7.3.20.1. Company Overview
    • 7.3.20.2. Financial Performance
    • 7.3.20.3. Product Benchmarking
    • 7.3.20.4. Strategic Initiatives
  • 7.3.21. Gladiator Therapeutics
    • 7.3.21.1. Company Overview
    • 7.3.21.2. Financial Performance
    • 7.3.21.3. Product Benchmarking
    • 7.3.21.4. Strategic Initiatives
  • 7.3.22. PAIN MANAGEMENT TECHNOLOGIES, INC.
    • 7.3.22.1. Company Overview
    • 7.3.22.2. Financial Performance
    • 7.3.22.3. Product Benchmarking
    • 7.3.22.4. Strategic Initiatives
  • 7.3.23. PainPod
    • 7.3.23.1. Company Overview
    • 7.3.23.2. Financial Performance
    • 7.3.23.3. Product Benchmarking
    • 7.3.23.4. Strategic Initiatives
  • 7.3.24. BioWave Corporation
    • 7.3.24.1. Company Overview
    • 7.3.24.2. Financial Performance
    • 7.3.24.3. Product Benchmarking
    • 7.3.24.4. Strategic Initiatives
  • 7.3.25. DIS&L
    • 7.3.25.1. Company Overview
    • 7.3.25.2. Financial Performance
    • 7.3.25.3. Product Benchmarking
    • 7.3.25.4. Strategic Initiatives
  • 7.3.26. TrueRelief, LLC
    • 7.3.26.1. Company Overview
    • 7.3.26.2. Financial Performance
    • 7.3.26.3. Product Benchmarking
    • 7.3.26.4. Strategic Initiatives
  • 7.3.27. MAI Medical
    • 7.3.27.1. Company Overview
    • 7.3.27.2. Financial Performance
    • 7.3.27.3. Product Benchmarking
    • 7.3.27.4. Strategic Initiatives
  • 7.3.28. Compex
    • 7.3.28.1. Company Overview
    • 7.3.28.2. Financial Performance
    • 7.3.28.3. Product Benchmarking
    • 7.3.28.4. Strategic Initiatives
  • 7.3.29. Pain Care Labs
    • 7.3.29.1. Company Overview
    • 7.3.29.2. Financial Performance
    • 7.3.29.3. Product Benchmarking
    • 7.3.29.4. Strategic Initiatives
  • 7.3.30. PowerCure Europe
    • 7.3.30.1. Company Overview
    • 7.3.30.2. Financial Performance
    • 7.3.30.3. Product Benchmarking
    • 7.3.30.4. Strategic Initiatives
• 7.4. Company Profiles, R&D Focus and Sales Channel Analysis
  • 7.4.1. PAJUNK
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. OMRON Healthcare, Inc.
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Zynex Medical
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Litemed
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. DJO Global
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Boston Scientific Corporation
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. SPR
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Medtronic
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Nalu Medical, Inc.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Abbott
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. Atricure, Inc.
    • 7.4.11.1. Company Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. ThermaCare
    • 7.4.12.1. Company Overview
    • 7.4.12.2. Financial Performance
    • 7.4.12.3. Product Benchmarking
    • 7.4.12.4. Strategic Initiatives
  • 7.4.13. Avanos Medical, Inc
    • 7.4.13.1. Company Overview
    • 7.4.13.2. Financial Performance
    • 7.4.13.3. Product Benchmarking
    • 7.4.13.4. Strategic Initiatives
  • 7.4.14. ICU Medical, Inc.
    • 7.4.14.1. Company Overview
    • 7.4.14.2. Financial Performance
    • 7.4.14.3. Product Benchmarking
    • 7.4.14.4. Strategic Initiatives
  • 7.4.15. Dynatronics Corporation
    • 7.4.15.1. Company Overview
    • 7.4.15.2. Financial Performance
    • 7.4.15.3. Product Benchmarking
    • 7.4.15.4. Strategic Initiatives
  • 7.4.16. RS Medical
    • 7.4.16.1. Company Overview
    • 7.4.16.2. Financial Performance
    • 7.4.16.3. Product Benchmarking
    • 7.4.16.4. Strategic Initiatives
  • 7.4.17. Bioventus
    • 7.4.17.1. Company Overview
    • 7.4.17.2. Financial Performance
    • 7.4.17.3. Product Benchmarking
    • 7.4.17.4. Strategic Initiatives
  • 7.4.18. BioElectronics Corporation
    • 7.4.18.1. Company Overview
    • 7.4.18.2. Financial Performance
    • 7.4.18.3. Product Benchmarking
    • 7.4.18.4. Strategic Initiatives
  • 7.4.19. ProMedTek Inc.
    • 7.4.19.1. Company Overview
    • 7.4.19.2. Financial Performance
    • 7.4.19.3. Product Benchmarking
    • 7.4.19.4. Strategic Initiatives
  • 7.4.20. InfuSystem
    • 7.4.20.1. Company Overview
    • 7.4.20.2. Financial Performance
    • 7.4.20.3. Product Benchmarking
    • 7.4.20.4. Strategic Initiatives
  • 7.4.21. Gladiator Therapeutics
    • 7.4.21.1. Company Overview
    • 7.4.21.2. Financial Performance
    • 7.4.21.3. Product Benchmarking
    • 7.4.21.4. Strategic Initiatives
  • 7.4.22. PAIN MANAGEMENT TECHNOLOGIES, INC.
    • 7.4.22.1. Company Overview
    • 7.4.22.2. Financial Performance
    • 7.4.22.3. Product Benchmarking
    • 7.4.22.4. Strategic Initiatives
  • 7.4.23. PainPod
    • 7.4.23.1. Company Overview
    • 7.4.23.2. Financial Performance
    • 7.4.23.3. Product Benchmarking
    • 7.4.23.4. Strategic Initiatives
  • 7.4.24. BioWave Corporation
    • 7.4.24.1. Company Overview
    • 7.4.24.2. Financial Performance
    • 7.4.24.3. Product Benchmarking
    • 7.4.24.4. Strategic Initiatives
  • 7.4.25. DIS&L
    • 7.4.25.1. Company Overview
    • 7.4.25.2. Financial Performance
    • 7.4.25.3. Product Benchmarking
    • 7.4.25.4. Strategic Initiatives
  • 7.4.26. TrueRelief, LLC
    • 7.4.26.1. Company Overview
    • 7.4.26.2. Financial Performance
    • 7.4.26.3. Product Benchmarking
    • 7.4.26.4. Strategic Initiatives
  • 7.4.27. MAI Medical
    • 7.4.27.1. Company Overview
    • 7.4.27.2. Financial Performance
    • 7.4.27.3. Product Benchmarking
    • 7.4.27.4. Strategic Initiatives
  • 7.4.28. Compex
    • 7.4.28.1. Company Overview
    • 7.4.28.2. Financial Performance
    • 7.4.28.3. Product Benchmarking
    • 7.4.28.4. Strategic Initiatives
  • 7.4.29. Pain Care Labs
    • 7.4.29.1. Company Overview
    • 7.4.29.2. Financial Performance
    • 7.4.29.3. Product Benchmarking
    • 7.4.29.4. Strategic Initiatives
  • 7.4.30. PowerCure Europe
    • 7.4.30.1. Company Overview
    • 7.4.30.2. Financial Performance
    • 7.4.30.3. Product Benchmarking
    • 7.4.30.4. Strategic Initiatives
• 7.5. Company Profiles, EMS Providers In Pearl River Delta
  • 7.5.1. Shenzhen WELLD Medical Electronics Co., Ltd.
    • 7.5.1.1. Company Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Longest Medical
    • 7.5.2.1. Company Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Shenzhen Roundwhale Technology Co., Ltd
    • 7.5.3.1. Company Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Shenzhen Xinmaikang Technology Co., Ltd.
    • 7.5.4.1. Company Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Huizhou Huan Dong Industrial Co., Ltd.
    • 7.5.5.1. Company Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Yunblaze Technology China
    • 7.5.6.1. Company Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Hong Qiangxing (Shenzhen) Electronics Limited
    • 7.5.7.1. Company Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Shenzhen Jrw Technology Co., Ltd.
    • 7.5.8.1. Company Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Quanding Medical
    • 7.5.9.1. Company Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Shenzhen Xinkang Health Technology Co., Ltd.
    • 7.5.10.1. Company Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives